(LXRX) Lexicon Pharmaceuticals - Ratings and Ratios
Sotagliflozin, LX9211, LX9851
LXRX EPS (Earnings per Share)
LXRX Revenue
Description: LXRX Lexicon Pharmaceuticals October 26, 2025
Lexicon Pharmaceuticals (NASDAQ:LXRX) is a U.S.-based biopharma focused on discovering, developing, and commercializing small-molecule therapies for cardiovascular, metabolic, and renal diseases. Its lead product, sotagliflozin, is positioned to lower cardiovascular death and heart-failure hospitalizations in patients with heart failure, type-2 diabetes, or chronic kidney disease, while additional candidates in Phase 3 (sotagliflozin for hypertrophic cardiomyopathy and type-1 diabetes), Phase 2 (LX9211 for neuropathic pain), and early development (LX9851 for obesity and cardiometabolic risk) expand its pipeline. The firm leverages strategic collaborations with Viatris and Bristol-Myers Squibb to broaden market reach and share development costs.
Key recent metrics: LXRX reported $85 million in total revenue for Q2 2024, driven largely by sotagliflozin sales under the Viatris partnership, and held $560 million in cash and equivalents, giving it roughly 18 months of runway at current burn rates. The biotech sector’s valuation is currently supported by a 12-month average price-to-sales multiple of ~7× for comparable small-molecule cardiovascular assets, and FDA’s recent guidance on heart-failure endpoints could accelerate approval timelines for Lexicon’s Phase 3 trials. However, the company’s valuation remains sensitive to the outcome of the HCM trial and competitive pressure from larger SGLT-2 inhibitors such as empagliflozin and dapagliflozin.
For a deeper, data-driven view of Lexicon’s risk-adjusted upside, you may find ValueRay’s analyst toolkit useful for further research.
LXRX Stock Overview
| Market Cap in USD | 501m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2000-04-07 |
LXRX Stock Ratings
| Growth Rating | -15.2% |
| Fundamental | 49.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -5.48% |
| Analyst Rating | 3.80 of 5 |
LXRX Dividends
Currently no dividends paidLXRX Growth Ratios
| Growth Correlation 3m | 76.5% |
| Growth Correlation 12m | 46.3% |
| Growth Correlation 5y | -80.8% |
| CAGR 5y | -12.89% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.14 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.25 |
| Sharpe Ratio 12m | -1.08 |
| Alpha | -54.11 |
| Beta | 1.237 |
| Volatility | 83.29% |
| Current Volume | 1111.3k |
| Average Volume 20d | 2202.3k |
| Stop Loss | 1.2 (-13%) |
| Signal | 0.50 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-120.6m TTM) > 0 and > 6% of Revenue (6% = 3.51m TTM) |
| FCFTA -0.46 (>2.0%) and ΔFCFTA 7.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 188.7% (prev 8046 %; Δ -7858 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.45 (>3.0%) and CFO -101.9m > Net Income -120.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (363.6m) change vs 12m ago 16.97% (target <= -2.0% for YES) |
| Gross Margin 98.87% (prev 84.48%; Δ 14.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 19.51% (prev 0.98%; Δ 18.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.78 (EBITDA TTM -109.8m / Interest Expense TTM 12.6m) >= 6 (WARN >= 3) |
Altman Z'' -49.74
| (A) 0.49 = (Total Current Assets 145.1m - Total Current Liabilities 34.8m) / Total Assets 225.6m |
| (B) -8.82 = Retained Earnings (Balance) -1.99b / Total Assets 225.6m |
| warn (B) unusual magnitude: -8.82 — check mapping/units |
| (C) -0.37 = EBIT TTM -110.4m / Avg Total Assets 299.5m |
| (D) -20.69 = Book Value of Equity -1.99b / Total Liabilities 96.1m |
| Total Rating: -49.74 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.74
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -24.22% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.47 = 2.39 |
| 5. Debt/Ebitda -0.36 = -2.50 |
| 7. RoE -83.63% = -2.50 |
| 8. Rev. Trend 91.44% = 6.86 |
| 9. EPS Trend 79.93% = 4.00 |
What is the price of LXRX shares?
Over the past week, the price has changed by -0.72%, over one month by +0.00%, over three months by +23.21% and over the past year by +14.52%.
Is Lexicon Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LXRX is around 1.25 USD . This means that LXRX is currently overvalued and has a potential downside of -9.42%.
Is LXRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LXRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.8 | 99.3% |
| Analysts Target Price | 2.8 | 99.3% |
| ValueRay Target Price | 1.4 | 2.2% |
LXRX Fundamental Data Overview November 02, 2025
P/S = 8.5825
P/B = 3.8743
P/EG = -0.14
Beta = 1.237
Revenue TTM = 58.4m USD
EBIT TTM = -110.4m USD
EBITDA TTM = -109.8m USD
Long Term Debt = 56.1m USD (from longTermDebt, last quarter)
Short Term Debt = 909.0k USD (from shortTermDebt, last quarter)
Debt = 61.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 40.1m USD (from netDebt column, last quarter)
Enterprise Value = 423.9m USD (501.5m + Debt 61.5m - CCE 139.0m)
Interest Coverage Ratio = -8.78 (Ebit TTM -110.4m / Interest Expense TTM 12.6m)
FCF Yield = -24.22% (FCF TTM -102.7m / Enterprise Value 423.9m)
FCF Margin = -175.7% (FCF TTM -102.7m / Revenue TTM 58.4m)
Net Margin = -206.4% (Net Income TTM -120.6m / Revenue TTM 58.4m)
Gross Margin = 98.87% ((Revenue TTM 58.4m - Cost of Revenue TTM 658.0k) / Revenue TTM)
Gross Margin QoQ = 99.28% (prev 97.62%)
Tobins Q-Ratio = 1.88 (Enterprise Value 423.9m / Total Assets 225.6m)
Interest Expense / Debt = 3.77% (Interest Expense 2.32m / Debt 61.5m)
Taxrate = 100.0% (out of range, set to none) (-200.4m / -200.4m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 4.16 (Total Current Assets 145.1m / Total Current Liabilities 34.8m)
Debt / Equity = 0.47 (Debt 61.5m / totalStockholderEquity, last quarter 129.4m)
Debt / EBITDA = -0.36 (negative EBITDA) (Net Debt 40.1m / EBITDA -109.8m)
Debt / FCF = -0.39 (negative FCF - burning cash) (Net Debt 40.1m / FCF TTM -102.7m)
Total Stockholder Equity = 144.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.47% (Net Income -120.6m / Total Assets 225.6m)
RoE = -83.63% (Net Income TTM -120.6m / Total Stockholder Equity 144.2m)
RoCE = -55.13% (EBIT -110.4m / Capital Employed (Equity 144.2m + L.T.Debt 56.1m))
RoIC = -213.5% (out of range, set to none) (EBIT -110.4m / (Assets 225.6m - Curr.Liab 34.8m - Cash 139.0m))
WACC = 9.42% (E(501.5m)/V(562.9m) * Re(10.57%) + (debt cost/tax rate unavailable))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 38.84%
Fair Price DCF = unknown (Cash Flow -102.7m)
EPS Correlation: 79.93 | EPS CAGR: 50.50% | SUE: 1.80 | # QB: 4
Revenue Correlation: 91.44 | Revenue CAGR: 1005 % | SUE: 3.28 | # QB: 1
Additional Sources for LXRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle